Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 218

Sort by

Sort Order Select

Journal Articles

High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas

Blood (2022) 140 (Supplement 1): 1183–1184.

https://doi.org/10.1182/blood-2022-156121

Published: 2022

Journal Articles

Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant

Blood (2022) 140 (Supplement 1): 284–286.

https://doi.org/10.1182/blood-2022-157960

Published: 2022

Journal Articles

Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis

Rohtesh S. Mehta, Rima M. Saliba, Amin M Alousi, Gheath Alatrash, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, Issa F. Khouri, Yago Nieto, Betul Oran, Uday R Popat, Muzaffar H Qazilbash, Jeremy L. Ramdial, Gabriela Rondon, Samer A Srour, Katy Rezvani, Richard E Champlin, Elizabeth J Shpall, Kai Cao

Blood (2022) 140 (Supplement 1): 7649–7650.

https://doi.org/10.1182/blood-2022-166381

Published: 2022

Journal Articles

Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond

Oren Pasvolsky, Rima M. Saliba, Celina Ledesma, Uday R Popat, Amin M Alousi, Amanda L. Olson, Betul Oran, Chitra Hosing, Qaiser Bashir, Muzaffar H Qazilbash, Nicholas Short, Farhad Ravandi, Richard E Champlin, Elizabeth J Shpall, Partow Kebriaei

Blood (2022) 140 (Supplement 1): 7695–7696.

https://doi.org/10.1182/blood-2022-155916

Published: 2022

Journal Articles

HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT

Rohtesh S. Mehta, Rima M. Saliba, Amin M. Alousi, Gheath Alatrash, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, Issa F. Khouri, Yago Nieto, Betul Oran, Uday R. Popat, Muzaffar H. Qazilbash, Jeremy L. Ramdial, Gabriela Rondon, Samer A. Srour, Katy Rezvani, Richard E. Champlin, Elizabeth J. Shpall, Kai Cao

Blood (2022) 140 (Supplement 1): 4880–4881.

https://doi.org/10.1182/blood-2022-158689

Published: 2022

Journal Articles

Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis

Rohtesh S. Mehta, Rima M. Saliba, Amin M Alousi, Gheath Alatrash, Qaiser Bashir, Partow Kebriaei, Issa F. Khouri, Yago Nieto, Betul Oran, Uday R Popat, Muzaffar H Qazilbash, Jeremy L. Ramdial, Gabriela Rondon, Samer A Srour, Katy Rezvani, Richard E Champlin, Elizabeth J Shpall, Kai Cao

Blood (2022) 140 (Supplement 1): 10530–10531.

https://doi.org/10.1182/blood-2022-166472

Published: 2022

Journal Articles

Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience

Oren Pasvolsky, Denái R Milton, Adeel Masood, Sophiya S Shehzad, Mark R Tanner, Qaiser Bashir, Samer A Srour, Neeraj Saini, Jeremy L. Ramdial, Yago Nieto, Hans C. Lee, Krina Patel, Partow Kebriaei, Sheeba K Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J Shpall, Richard E Champlin, Muzaffar H Qazilbash

Blood (2022) 140 (Supplement 1): 10589–10591.

https://doi.org/10.1182/blood-2022-162465

Published: 2022

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort

Naveen Pemmaraju, Hagop Kantarjian, Joseph D. Khoury, Nitin Jain, Muzaffar H Qazilbash, Sanam Loghavi, Sherry A. Pierce, Keyur P. Patel, Guillermo Garcia-Manero, Elias Jabbour, Naval Daver, Gautam Borthakur, Marina Konopleva

Blood (2022) 140 (Supplement 1): 1293–1294.

https://doi.org/10.1182/blood-2022-170956

Published: 2022

Journal Articles

Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis

Blood (2022) 140 (Supplement 1): 2232–2233.

https://doi.org/10.1182/blood-2022-160294

Published: 2022

Journal Articles

Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis

Hans C. Lee, Gregory P. Kaufman, Lei Feng, Astrid Murga, Ralph J. Johnson, Donna M. Weber, Sheeba K Thomas, Qaiser Bashir, Muzaffar H Qazilbash, Swaminathan P. Iyer, Krina Patel, Melody R. Becnel, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 4428–4430.

https://doi.org/10.1182/blood-2022-167555

Published: 2022

Journal Articles

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma

Blood (2022) 139 (9): 1289–1301.

https://doi.org/10.1182/blood.2020008493

Published: 2022

Includes: Supplemental data

Journal Articles

Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial

Blood (2021) 138 (Supplement 1): 2879.

https://doi.org/10.1182/blood-2021-146253

Published: 2021

Journal Articles

Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplant (ASCT) for Patients with POEMS Syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes): A CIBMTR Analysis

Ankit Kansagra, Angela Dispenzieri, Raphael Fraser, Noel Estrada-Merly, Shaji Kumar, Muzaffar H. Qazilbash, Nina Shah, Anita D'Souza

Blood (2021) 138 (Supplement 1): 120.

https://doi.org/10.1182/blood-2021-151325

Published: 2021

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy

Blessie Elizabeth Nelson, Jeremy L. Ramdial, Qaiser Bashir, Neeraj Saini, Chitra Hosing, Uday R. Popat, Ruby Delgado, Hans C. Lee, Gregory P. Kaufman, Robert Z. Orlowski, Richard E. Champlin, Muzaffar H. Qazilbash, Samer A. Srour

Blood (2021) 138 (Supplement 1): 482.

https://doi.org/10.1182/blood-2021-154277

Published: 2021

Journal Articles

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Blood (2021) 138 (Supplement 1): 475.

https://doi.org/10.1182/blood-2021-144296

Published: 2021

Journal Articles

Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial

Blood (2021) 138 (Supplement 1): 556.

https://doi.org/10.1182/blood-2021-152450

Published: 2021

Journal Articles

Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy

Naveen Pemmaraju, Nathaniel R Wilson, Guillermo Garcia-Manero, Koji Sasaki, Joseph D. Khoury, Nitin Jain, Gautam Borthakur, Farhad Ravandi, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo, Elias J. Jabbour, Sherry A. Pierce, John Villarreal, Muzaffar H. Qazilbash, Marina Konopleva, Hagop Kantarjian

Blood (2021) 138 (Supplement 1): 2319.

https://doi.org/10.1182/blood-2021-154205

Published: 2021

Journal Articles

Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 1779.

https://doi.org/10.1182/blood-2021-151474

Published: 2021

Journal Articles

Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial

Blood (2021) 138 (Supplement 1): 1802.

https://doi.org/10.1182/blood-2021-146655

Published: 2021

Journal Articles

Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial

Blood (2021) 138 (Supplement 1): 1803.

https://doi.org/10.1182/blood-2021-146245

Published: 2021

NARROW

High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas

Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant

Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis

Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond

HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT

Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis

Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort

Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis

Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma

Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial

Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplant (ASCT) for Patients with POEMS Syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes): A CIBMTR Analysis

Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial

Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy

Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation

Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial

Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only